...
首页> 外文期刊>Molecular Simulation >Molecular modelling study on human histamine H1 receptor and its applications in virtual lead identification for designing novel inverse agonists
【24h】

Molecular modelling study on human histamine H1 receptor and its applications in virtual lead identification for designing novel inverse agonists

机译:人类组胺H1受体的分子建模研究及其在虚拟铅鉴定中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Human histamine H1 receptor (HHR1) is one of the G protein-coupled receptors (GPCRs) known for their constitutive activation in the absence of agonist binding. Inverse agonists are the compounds that inhibit this constitutive activity of GPCRs. HHR1 is involved in allergic reactions and is also known to be constitutively active. An updated quantitative pharmacophore model, Hypo1, has been developed using a diverse set of known HHR1 inverse agonists employing the HypoGen algorithm as implemented in Accelrys Discovery Studio 2.1. Hypo1 comprised four pharmacophore features (each one of hydrogen bond acceptor, hydrophobic, ring aromatic and positive ionisable group) along with a high correlation value of 0.944. This pharmacophore model was validated using an external test set containing 25 diverse inverse agonists and CatScramble method. Three chemical databases were screened for novel chemical scaffolds using Hypo1 as a query, to be utilised in drug design. The 3D structure of HHR1 has been constructed using human β2 adrenergic receptor. Molecular docking studies were performed with the database hit compounds using GOLD 4.1 program. The combination of all results led us to identify novel compounds to be deployed in designing new generation HHR1 inverse agonists.View full textDownload full textKeywordspharmacophore, homology modelling, inverse agonists, histamine H1 receptor, database screeningRelated var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; Add to shortlist Link Permalink http://dx.doi.org/10.1080/08927022.2010.524645
机译:人组胺H1受体(HHR1)是一种G蛋白偶联受体(GPCR),以其在没有激动剂结合的情况下的组成型激活而闻名。反向激动剂是抑制GPCR这种组成活性的化合物。 HHR1参与过敏反应,并且还已知具有组成性活性。使用Accelrys Discovery Studio 2.1中实施的HypoGen算法,使用多种已知的HHR1反向激动剂,开发了一种更新的定量药效团模型Hypo1。 Hypo1包含四个药效基团特征(氢键受体,疏水基,环芳基和可正电离的基团之一)以及0.944的高相关值。使用包含25种不同的反向激动剂和CatScramble方法的外部测试集验证了该药效团模型。使用Hypo1作为查询,筛选了三个化学数据库中的新型化学支架,以用于药物设计。 HHR1的3D结构已使用人β2肾上腺素受体构造。使用GOLD 4.1程序对数据库命中的化合物进行了分子对接研究。所有结果的结合使我们确定了可用于设计新一代HHR1反向激动剂的新型化合物。查看全文下载全文关键字药效团,同源性建模,反向激动剂,组胺H1受体,数据库筛选相关的var addthis_config = {ui_cobrand:“ Taylor&Francis在线”,services_compact:“ citeulike,netvibes,twitter,technorati,可口,linkedin,facebook,stumbleupon,digg,google,更多”,发布号:“ ra-4dff56cd6bb1830b”};添加到候选列表链接永久链接http://dx.doi.org/10.1080/08927022.2010.524645

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号